EUVIMEDEUVIMED entdecken
Crossref

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer

Robin Beekhof iD, Andrea Bertotti iD, Franziska Böttger iD, Valentina Vurchio iD, Francesca Cottino iD, Eugenia R Zanella iD, Giorgia Migliardi iD, Marco Viviani iD, Elena Grassi iD, Barbara Lupo iD, Alex A Henneman iD, Jaco C Knol und 7 weitere

Science Translational Medicine · 2023

DOI: 10.1126/scitranslmed.abm3687 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2023. Verfasst von Robin Beekhof und 18 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colonic Neoplasms, Colorectal Neoplasms. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 63 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) is a well-exploited therapeutic target in metastatic colorectal cancer (mCRC). Unfortunately, not all patients benefit from current EGFR inhibitors. Mass spectrometry–based proteomics and phosphoproteomics were performed on 30 genomically and pharmacologically characterized mCRC patient–derived xenografts (PDXs) to investigate the molecular basis of response to EGFR blockade and identify alternative drug targets to overcome resistance. Both the tyrosine and global phosphoproteome as well as the proteome harbored distinctive response signatures. We found that increased pathway activity related to mitogen-activated protein kinase (MAPK) inhibition and abundant tyrosine phosphorylation of cell junction proteins, such as CXADR and CLDN1/3, in sensitive tumors, whereas epithelial-mesenchymal transition and increased MAPK and AKT signaling were more prevalent in resistant tumors. Furthermore, the ranking of kinase activities in single samples confirmed the driver activity of ERBB2, EGFR, and MET in cetuximab-resistant tumors. This analysis also revealed high kinase activity of several members of the Src and ephrin kinase family in 2 CRC PDX models with genomically unexplained resistance. Inhibition of these hyperactive kinases, alone or in combination with cetuximab, resulted in growth inhibition of ex vivo PDX-derived organoids and in vivo PDXs. Together, these findings highlight the potential value of phosphoproteomics to improve our understanding of anti-EGFR treatment and response prediction in mCRC and bring to the forefront alternative drug targets in cetuximab-resistant tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsColonic NeoplasmsColorectal NeoplasmsHumansAntibodies, Monoclonal, HumanizedCell Line, TumorCetuximabDrug Resistance, NeoplasmMitogen-Activated Protein KinasesPhosphorylationSignal TransductionPhosphoproteinsProteome

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsCetuximabMitogen-Activated Protein KinasesPhosphoproteinsProteome

Autor:innen und Institutionen

  • Amsterdam UMC, Vrije Universiteit Amsterdam, Medical Oncology, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.
  • Amsterdam UMC, Vrije Universiteit Amsterdam, OncoProteomics Laboratory, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, Netherlands.
  • Candiolo Cancer Institute - FPO IRCCS, Candiolo, 10060 Torino, Italy.
  • Department of Oncology, University of Torino, Candiolo, 10060 Torino, Italy.
  • Division of Molecular Carcinogenesis, Netherlands Cancer Institute, Oncode Institute, 1066 CX Amsterdam, Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, Netherlands.

ORCID-Profile: Robin Beekhof, Andrea Bertotti, Franziska Böttger, Valentina Vurchio, Francesca Cottino, Eugenia R Zanella, Giorgia Migliardi, Marco Viviani, Elena Grassi, Barbara Lupo, Alex A Henneman, Thang V Pham, Sander R Piersma, Mariette Labots, Henk M W Verheul, Livio Trusolino, Connie R Jimenez

Zitieren

APA

Beekhof, R., Bertotti, A., Böttger, F., Vurchio, V., Cottino, F., Zanella, E. R., Migliardi, G., Viviani, M., Grassi, E., Lupo, B., Henneman, A. A., Knol, J. C., Pham, T. V., de Goeij-de Haas, R., Piersma, S. R., Labots, M., Verheul, H. M. W., Trusolino, L., & Jimenez, C. R. (2023). Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.abm3687

Vancouver

Beekhof R, Bertotti A, Böttger F, Vurchio V, Cottino F, Zanella ER, et al. Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer. Science Translational Medicine. 2023. doi:10.1126/scitranslmed.abm3687

BibTeX
@article{Beekhof2023,
  author = {Beekhof, Robin and Bertotti, Andrea and Böttger, Franziska and Vurchio, Valentina and Cottino, Francesca and Zanella, Eugenia R and Migliardi, Giorgia and Viviani, Marco and Grassi, Elena and Lupo, Barbara and Henneman, Alex A and Knol, Jaco C and Pham, Thang V and de Goeij-de Haas, Richard and Piersma, Sander R and Labots, Mariette and Verheul, Henk M W and Trusolino, Livio and Jimenez, Connie R},
  title = {Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer},
  journal = {Science Translational Medicine},
  year = {2023},
  doi = {10.1126/scitranslmed.abm3687}
}
Kostenlos starten →